Novartis Q4 Results
Content
Click below to navigate
through the document
Company overview
Financial review
Novartis continues to deliver strong operational performance over
a number of years...
Continuing operations¹ performance, numbers restated post-Sandoz spin-off
FINANCIAL PROFILE
↓
↑
Conclusions
Appendix
References
Net sales
USDbn, % cc
+7% CAGR
+7%
+10%
+5%
+4%
+12%
35.2
Core Oplnc²
USDbn, % cc
+14% CAGR
+12%
+18%
+10%
+13%
+20%
10.1
Core margin²
%
+990bps cc
36.0
35.1
33.9
32.4
30.6
28.7
2018 2019 2020
2021
2022
2023
2018
2019 2020 2021
2022
2023
2018
2019
2020 2021 2022 2023
USDbn 35.2 38.1
39.5 42.8 42.2
45.4
10.1
11.7
12.8
14.5
14.8
16.4
1. As defined on page 37 of the Condensed Financial Report, Continuing operations include the retained business activities of Novartis, comprising the Innovative Medicines Division and the continuing Corporate activities.
constant currencies are non-IFRS measures. Details regarding non-IFRS measures can be found starting on page 49 of the Condensed Financial Report. Unless otherwise noted, all growth rates refer to same period in PY.
2. Core results and
□ NOVARTIS | Reimagining Medicine.
Novartis Q4 Results | January 31, 2024
25View entire presentation